Di Giacomo AM

Publications (4)13.25 Total impact

• Article: Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010

  Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, [......], Matera L, Perego M, Pietra G, Pilla L, Proietti E, Santoni A, Stecca B, Rivoltini L, van der Burg SH, Parmiani G
  Cancer Immunology and Immunotherapy 06/2011; 60(6):901-7. · 3.70 Impact Factor
• Article: Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

  Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, [......], Maccalli C, Melero I, Monsurrò V, Montagna D, Moschella F, Ponzoni M, Protti MP, Puccetti P, Sangiolo D, Schuler G
  Cancer Immunology and Immunotherapy 12/2010; 59(12):1895-901. · 3.70 Impact Factor
• Article: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

  Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M
  Cancer Immunology and Immunotherapy 08/2009; · 3.70 Impact Factor
• Article: Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments?

  Calabrò L, Di Giacomo AM, Altomonte M, Fonsatti E, Mazzei MA, Volterrani L, Miracco C, Maio M
  Journal of Experimental & Clinical Cancer Research 03/2007; · 2.15 Impact Factor